| Medical and Health Sciences | Lifetime | 93 | US 51 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 22 | US 12 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 28 | US 20 | 99.98 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 42 | US 23 | 99.86 |
| Surgery | Lifetime | 335 | US 187 | 99.71 |
| Pulmonary and Respiratory Medicine | Lifetime | 458 | US 242 | 99.40 |
| Complementary and Alternative Medicine | Lifetime | 301 | US 110 | 98.50 |
| Nephrology | Lifetime | 573 | US 274 | 93.37 |
| Hematology | Lifetime | 903 | US 443 | 90.72 |
| Statistics, Probability and Uncertainty | Lifetime | 1,000 | US 393 | 86.76 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 11 | US 6 | 99.95 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 11 | US 8 | 99.93 |
| Surgery | 2021-2025 | 82 | US 36 | 99.53 |
| Hematology | 2021-2025 | 76 | US 41 | 98.31 |
| Molecular Biology | 2021-2025 | 495 | US 135 | 97.47 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 279 | US 87 | 97.55 |
| Nephrology | 2021-2025 | 70 | US 29 | 97.50 |
| Complementary and Alternative Medicine | 2021-2025 | 141 | US 32 | 93.64 |
| Medical Genetics | 2021-2025 | 189 | US 87 | 91.49 |
| Clinical Pharmacology | 2021-2025 | 344 | US 99 | 85.28 |
| Cardiac pacing and defibrillation studies | Lifetime | 9 | US 7 | 99.94 |
| Cardiovascular Function and Risk Factors | Lifetime | 13 | US 11 | 99.96 |
| Diabetes Treatment and Management | Lifetime | 8 | US 4 | 99.92 |
| Heart Failure Treatment and Management | Lifetime | 6 | US 6 | 99.96 |
| Potassium and Related Disorders | Lifetime | 3 | US 3 | 99.88 |
| Pancreatic function and diabetes | Lifetime | 37 | US 21 | 99.79 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 42 | US 22 | 99.80 |
| Electrolyte and hormonal disorders | Lifetime | 31 | US 17 | 99.36 |
| Hemodynamic Monitoring and Therapy | Lifetime | 49 | US 15 | 99.49 |
| Metabolism, Diabetes, and Cancer | Lifetime | 82 | US 42 | 99.57 |
| Cardiovascular Disease and Adiposity | Lifetime | 95 | US 62 | 99.43 |
| Blood Pressure and Hypertension Studies | Lifetime | 161 | US 71 | 99.42 |
| Erythropoietin and Anemia Treatment | Lifetime | 39 | US 16 | 99.11 |
| Heart Rate Variability and Autonomic Control | Lifetime | 257 | US 120 | 98.93 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 219 | US 105 | 98.78 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 453 | US 192 | 98.87 |
| Hormonal Regulation and Hypertension | Lifetime | 335 | US 145 | 98.38 |
| Cardiovascular and exercise physiology | Lifetime | 347 | US 135 | 98.42 |
| Cardiac Structural Anomalies and Repair | Lifetime | 498 | US 302 | 98.55 |
| Mechanical Circulatory Support Devices | Lifetime | 610 | US 364 | 97.62 |
| Iron Metabolism and Disorders | Lifetime | 528 | US 240 | 96.94 |
| Heart rate and cardiovascular health | Lifetime | 55 | US 21 | 95.92 |
| Renin-Angiotensin System Studies | Lifetime | 374 | US 157 | 96.53 |
| Cardiac Health and Mental Health | Lifetime | 884 | US 410 | 94.95 |
| Chronic Kidney Disease and Diabetes | Lifetime | 842 | US 341 | 95.65 |
| Pharmacology and Obesity Treatment | Lifetime | 525 | US 222 | 94.70 |
| Medication Adherence and Compliance | Lifetime | 489 | US 268 | 93.89 |
| Meta-analysis and systematic reviews | Lifetime | 790 | US 248 | 91.63 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 817 | US 234 | 88.42 |
| Pancreatic function and diabetes | 2021-2025 | 3 | US 2 | 99.90 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 12 | US 8 | 99.92 |
| Diabetes Treatment and Management | 2021-2025 | 12 | US 8 | 99.91 |
| Iron Metabolism and Disorders | 2021-2025 | 5 | US 3 | 99.38 |
| Heart Failure Treatment and Management | 2021-2025 | 14 | US 10 | 99.88 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 10 | US 7 | 99.65 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 15 | US 8 | 98.89 |
| Potassium and Related Disorders | 2021-2025 | 3 | US 2 | 99.58 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 4 | US 3 | 99.72 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 49 | US 18 | 98.66 |
| Diabetes Management and Research | 2021-2025 | 209 | US 110 | 97.17 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 235 | US 94 | 97.15 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 727 | US 192 | 91.51 |
| Dialysis and Renal Disease Management | 2021-2025 | 547 | US 126 | 91.19 |
| Hormonal Regulation and Hypertension | 2021-2025 | 373 | US 86 | 88.95 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 873 | US 214 | 87.25 |
| Pharmacology and Obesity Treatment | 2021-2025 | 195 | US 91 | 85.59 |
| Electrolyte and hormonal disorders | 2021-2025 | 230 | US 77 | 83.77 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 947 | US 235 | 81.43 |
| Apelin-related biomedical research | 2021-2025 | 206 | US 33 | 67.72 |
| GDF15 and Related Biomarkers | 2021-2025 | 823 | US 201 | 46.29 |